Diabetic nephropathy and endothelial dysfunction: Current and future therapies, and emerging of vascular imaging for preclinical renal-kinetic study

Life Sciences

Volumn 166, Issue , 2016, Pages 121-130

  Leung, Wilson KC ^a   Gao, L ^a   Siu, Parco M ^a   Lai, Christopher WK ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Diabetic nephropathy; Endothelial dysfunction; Molecular mechanism; Multispectral optoacoustic tomography; Therapy

Indexed keywords

ANGIOTENSIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GLUCOSE; NITRIC OXIDE; RENIN; VASCULOTROPIN;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; EXPERIMENTAL ANIMAL; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY PELVIS; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHOTOACOUSTIC TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG DEVELOPMENT; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; PHOTOACOUSTICS; PROCEDURES; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DRUG DISCOVERY; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY; PHOTOACOUSTIC TECHNIQUES;

EID: 84992365151     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.10.015     Document Type: Review

References (88)

1. [1] World Health Organization, Global Report on Diabetes. 2016, World Health Organization, Geneva.
2. [2] Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3, 2006, e442.
3. [3] GA, G.A.H., Type 2 Diabetes: Prediction and Prevention. 2007, Wiley-Blackwell, Hoboken.
4. [4] Karunakaran, U., Park, K.G., A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. Diabetes Metab. J. 37 (2013), 106–112.
5. [5] Li, B., Liu, S., Miao, L., Cai, L., Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Exp. Diabetes Res., 2012, 2012, 216512.
6. [6] Modak, M.A., Parab, P.B., Ghaskadbi, S.S., Tissue specific oxidative stress profile in relation to glycaemic regulation in mice. Diabetes Metab. Res. Rev. 30 (2014), 31–41.
7. [7] Fiorentino, T.V., Prioletta, A., Zuo, P., Folli, F., Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr. Pharm. Des. 19 (2013), 5695–5703.
8. [8] Paradies, G., Paradies, V., Ruggiero, F.M., Petrosillo, G., Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 14205–14218.
9. [9] Rai, P., Singh, T., Lederman, R., Chawla, A., Kumar, D., Cheng, K., Valecha, G., Mathieson, P.W., Saleem, M.A., Malhotra, A., Singhal, P.C., Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptors. Cell. Signal. 27 (2015), 460–469.
10. [10] Kumar, B., Kowluru, A., Kowluru, R.A., Lipotoxicity augments glucotoxicity-induced mitochondrial damage in the development of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 56 (2015), 2985–2992.
11. [11] Wu, Y., Tang, L., Chen, B., Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxidative Med. Cell. Longev., 2014, 2014, 752387.
12. [12] Sciacca, L., Vigneri, R., Tumminia, A., Frasca, F., Squatrito, S., Frittitta, L., Vigneri, P., Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr. Metab. Cardiovasc. Dis. 23 (2013), 808–815.
13. [13] Hayashi, T., Kotani, K., Yamaguchi, T., Taguchi, K., Iida, M., Ina, K., Maeda, M., Kuzuya, M., Hattori, Y., Ignarro, L.J., Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 1168–1173.
14. [14] Hayashi, T., Matsui-Hirai, H., Miyazaki-Akita, A., Fukatsu, A., Funami, J., Ding, Q.F., Kamalanathan, S., Hattori, Y., Ignarro, L.J., Iguchi, A., Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 17018–17023.
15. [15] Hayashi, T., Yamaguchi, T., Sakakibara, Y., Taguchi, K., Maeda, M., Kuzuya, M., Hattori, Y., eNOS-dependent antisenscence effect of a calcium channel blocker in human endothelial cells. PLoS One, 9, 2014, e88391.
16. [16] Matsui-Hirai, H., Hayashi, T., Yamamoto, S., Ina, K., Maeda, M., Kotani, H., Iguchi, A., Ignarro, L.J., Hattori, Y., Dose-dependent modulatory effects of insulin on glucose-induced endothelial senescence in vitro and in vivo: a relationship between telomeres and nitric oxide. J. Pharmacol. Exp. Ther. 337 (2011), 591–599.
17. [17] Christ, M., Bauersachs, J., Liebetrau, C., Heck, M., Günther, A., Wehling, M., Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor. Diabetes 51 (2002), 2648–2652.
18. [18] Sena, C.M., Pereira, A.M., Seiça, R., Endothelial dysfunction—a major mediator of diabetic vascular disease. Biochim. Biophys. Acta 1832 (2013), 2216–2231.
19. [19] Lai, W.K., Kan, M.Y., Homocysteine-induced endothelial dysfunction. Ann. Nutr. Metab. 67 (2015), 1–12.
20. [20] IF, I.F.S., Human Physiology. thirteenth ed, 2012, McGraw-Hill, New York.
21. [21] Martini, F.H., Bartholomew, E.F., Essentials of Anatomy and Physiology. sixth ed., 2013, Pearson, London.
22. [22] Birn, H., Christensen, E.I., Renal albumin absorption in physiology and pathology. Kidney Int. 69 (2006), 440–449.
23. [23] Martens, R.J., Henry, R.M., Houben, A.J., van der Kallen, C.J., Kroon, A.A., Schalkwijk, C.G., Schram, M.T., Sep, S.J., Schaper, N.C., Dagnelie, P.C., Muris, D.M., Gronenschild, E.H., van der Sande, F.M., Leunissen, K.M., Kooman, J.P., Stehouwer, C.D., Capillary rarefaction associates with albuminuria: the Maastricht study. J. Am. Soc. Nephrol., 2016 (pii ASN.2015111219).
24. [24] Mackawy, A.M., Khan, A.A., Badawy, M.S., Association of the endothelial nitric oxide synthase gene G894T polymorphism with the risk of diabetic nephropathy in Qassim region, Saudi Arabia—A pilot study. Meta. Gene. 2 (2014), 392–402.
25. [25] Petrica, L., Vlad, A., Gluhovschi, G., Gadalean, F., Dumitrascu, V., Gluhovschi, C., Velciov, S., Bob, F., Vlad, D., Popescu, R., Milas, O., Ursoniu, S., Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study. PLoS One, 9, 2014, e112538.
26. [26] Rafnsson, A., Bäck, M., Urinary leukotriene E4 is associated with renal function but not with endothelial function in type 2 diabetes. Dis. Markers 35 (2013), 475–480.
27. [27] Alkhalaf, A., Kleefstra, N., Groenier, K.H., Bilo, H.J., Gans, R.O., Heeringa, P., Scheijen, J.L., Schalkwijk, C.G., Navis, G.J., Bakker, S.J., Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One, 7, 2012, e40427.
28. [28] Rafnsson, A., Böhm, F., Settergren, M., Gonon, A., Brismar, K., Pernow, J., The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomized trial. Diabetologia 55 (2012), 600–607.
29. [29] Røndbjerg, A.K., Omerovic, E., Vestergaard, H., YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc. Diabetol., 10, 2010, 54.
30. [30] Lee, S.Y., Choi, M.E., Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr. Nephrol. 30 (2015), 1063–1075.
31. [31] Scarfe, L., Rak-Raszewska, A., Geraci, S., Darssan, D., Sharkey, J., Huang, J., Burton, N.C., Mason, D., Ranjzad, P., Kenny, S., Gretz, N., Lévy, R., Kevin, P.B., García-Fiñana, M., Woolf, A.S., Murray, P., Wilm, B., Measures of kidney function by minimally invasive techniques correlate with histological glomerular damage in SCID mice with adriamycin-induced nephropathy. Sci. Rep., 5, 2015, 13601.
32. [32] Bilous, R., Donnelly, R., Handbook of Diabetes. fourth ed., 2010, Wiley-Blackwell, Hoboken.
33. [33] Deanfield, J., Donald, A., Ferri, C., Giannattasio, C., Halcox, J., Halligan, S., Lerman, A., Mancia, G., Oliver, J.J., Pessina, A.C., Rizzoni, D., Rossi, G.P., Salvetti, A., Schiffrin, E.L., Taddei, S., Webb, D.J., Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension, Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 23 (2005), 7–17.
34. [34] Stankevicius, E., Kevelaitis, E., Vainorius, E., Simonsen, U., Role of nitric oxide and other endothelium-derived factors. Medicina (Kaunas) 39 (2003), 333–341.
35. [35] Marra, M., Marchegiani, F., Ceriello, A., Sirolla, C., Boemi, M., Franceschi, C., Spazzafumo, L., Testa, I., Bonfigli, A.R., Cucchi, M., Testa, R., Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects. Nephrol. Dial. Transplant. 28 (2013), 964–971.
36. [36] El-Din Bessa, S.S., Hamdy, S.M., Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients. Ren. Fail. 33 (2011), 878–884.
37. [37] Hirata, M., Serizawa, K., Aizawa, K., Yogo, K., Tashiro, Y., Takeda, S., Moriguchi, Y., Endo, K., Fukagawa, M., 22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type 2 diabetes and early-stage nephropathy. Nephrol. Dial. Transplant. 28 (2013), 1166–1174.
38. [38] Toblli, J.E., Cao, G., Giani, J.F., Muñoz, M.C., Angerosa, M., Dominici, F.P., Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. J. Hypertens. 29 (2011), 1613–1623.
39. [39] Zoja, C., Cattaneo, S., Fiordaliso, F., Lionetti, V., Zambelli, V., Salio, M., Corna, D., Pagani, C., Rottoli, D., Bisighini, C., Remuzzi, G., Benigni, A., Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am. J. Physiol. Renal Physiol. 301 (2011), F1114–F1123.
40. [40] Yilmaz, M.I., Sonmez, A., Saglam, M., Kurt, Y.G., Unal, H.U., Karaman, M., Gok, M., Cetinkaya, H., Eyileten, T., Oguz, Y., Vural, A., Mallamaci, F., Zoccali, C., Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. Am. J. Nephrol. 40 (2014), 208–214.
41. [41] Agarwal, R., Duffin, K.L., Laska, D.A., Voelker, J.R., Breyer, M.D., Mitchell, P.G., A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol. Dial. Transplant. 29 (2014), 2293–2302.
42. [42] Kohan, D.E., Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 29 (1997), 2–26.
43. [43] Meyers, K.E., Sethna, C., Endothelin antagonists in hypertension and kidney disease. Pediatr. Nephrol. 28 (2013), 711–720.
44. [44] Bouallegue, A., Daou, G.B., Srivastava, A.K., Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr. Vasc. Pharmacol. 5 (2007), 45–52.
45. [45] Mather, K.J., Mirzamohammadi, B., Lteif, A., Steinberg, H.O., Baron, A.D., Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51 (2002), 3517–3523.
46. [46] Takahashi, K., Ghatei, M.A., Lam, H.C., O'Halloran, D.J., Bloom, S.R., Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33 (1990), 306–310.
47. [47] Verhaar, M.C., Strachan, F.E., Newby, D.E., Cruden, N.L., Koomans, H.A., Rabelink, T.J., Webb, D.J., Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97 (1998), 752–756.
48. [48] Ahlborg, G., Lindström, J., Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans. J. Appl. Physiol. 93:2002 (1985), 2112–2121.
49. [49] Ak, G., Buyukberber, S., Sevinc, A., Turk, H.M., Ates, M., Sari, R., Savli, H., Cigli, A., The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J. Diabetes Complicat. 15 (2001), 150–157.
50. [50] De Mattia, G., Cassone-Faldetta, M., Bellini, C., Bravi, M.C., Laurenti, O., Baldoncini, R., Santucci, A., Ferri, C., Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am. J. Hypertens. 11 (1998), 983–988.
51. [51] Lee, Y.J., Shin, S.J., Tsai, J.H., Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care 17 (1994), 263–266.
52. [52] Zanatta, C.M., Gerchman, F., Burttet, L., Nabinger, G., Jacques-Silva, M.C., Canani, L.H., Gross, J.L., Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 80 (2008), 299–304.
53. [53] Doi, K., Noiri, E., Fujita, T., Role of vascular endothelial growth factor in kidney disease. Curr. Vasc. Pharmacol. 8 (2010), 122–128.
54. [54] Kacso, I.M., Bondor, C.I., Kacso, G., Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin. Biochem. 45 (2012), 1415–1420.
55. [55] Oltean, S., Qiu, Y., Ferguson, J.K., Stevens, M., Neal, C., Russell, A., Kaura, A., Arkill, K.P., Harris, K., Symonds, C., Lacey, K., Wijeyaratne, L., Gammons, M., Wylie, E., Hulse, R.P., Alsop, C., Cope, G., Damodaran, G., Betteridge, K.B., Ramnath, R., Satchell, S.C., Foster, R.R., Ballmer-Hofer, K., Donaldson, L.F., Barratt, J., Baelde, H.J., Harper, S.J., Bates, D.O., Salmon, A.H., Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J. Am. Soc. Nephrol. 26 (2015), 1889–1904.
56. [56] Vijay, S.K., Mishra, M., Kumar, H., Tripathi, K., Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 46 (2009), 27–33.
57. [57] Wang, J.Y., Lu, Q., Tao, Y., Jiang, Y.R., Jonas, J.B., Intraocular expression of thymosin β4 in proliferative diabetic retinopathy. Acta Ophthalmol. 89 (2011), e396–e403.
58. [58] Zhu, J., Su, L.P., Zhou, Y., Ye, L., Lee, K.O., Ma, J.H., Thymosin β4 attenuates early diabetic nephropathy in a mouse model of type 2 diabetes mellitus. Am. J. Ther. 22 (2015), 141–146.
59. [59] Cha, J.J., Kang, Y.S., Hyun, Y.Y., Han, S.Y., Jee, Y.H., Han, K.H., Han, J.Y., Cha, D.R., Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci. 92 (2013), 1118–1124.
60. [60] Nakagawa, T., Sato, W., Kosugi, T., Johnson, R.J., Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J. Diabetes Res., 2013, 2013, 184539.
61. [61] Nguyen, T., Nioi, P., Pickett, C.B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284 (2009), 13291–13295.
62. [62] Nath, K.A., Heme oxygenase-1 and acute kidney injury. Curr. Opin. Nephrol. Hypertens. 23 (2014), 17–24.
63. [63] Wang, L., Zhang, X., Chan, J.Y., Shan, L., Cui, G., Cui, Q., Wang, Y., Li, J., Chen, H., Zhang, Q., Yu, P., Han, Y., Wang, Y., Lee, S.M., A novel danshensu derivative prevents cardiac dysfunction and improves the chemotherapeutic efficacy of doxorubicin in breast cancer cells. J. Cell. Biochem. 117 (2016), 94–105.
64. [64] Yang, C., Zhang, X., Fan, H., Liu, Y., Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 1282 (2009), 133–141.
65. [65] Sahin, K., Tuzcu, M., Sahin, N., Ali, S., Kucuk, O., Nrf2/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene. Food Chem. Toxicol. 48 (2010), 2670–2674.
66. [66] Leong, P.K., Wong, H.S., Chen, J., Ko, K.M., Yang/Qi invigoration: an herbal therapy for chronic fatigue syndrome with yang deficiency?. Evid. Based Complement. Alternat. Med., 2015, 2015, 945901.
67. [67] Guan, Y., Wu, X.X., Duan, J.L., Yin, Y., Guo, C., Wei, G., Wang, Y.H., Zhu, Y.R., Weng, Y., Xi, M.M., Wen, A.D., Effects and mechanism of combination of Rhein and danshensu in the treatment of chronic kidney disease. Am. J. Chin. Med. 43 (2015), 1381–1400.
68. [68] Luo, J.A., Peng, Y.M., Xia, Y.C., Lei, Y., Therapeutic effects of Chinese drugs on early renal damage of rats caused by fish bile. Zhongguo Zhong Xi Yi Jie He Za Zhi 13 (1993), 98–99 (Article in Chinese).
69. [69] Ngai, H.H., Sit, W.H., Wan, J.M., The nephroprotective effects of the herbal medicine preparation, WH30 +, on the chemical-induced acute and chronic renal failure in rats. Am. J. Chin. Med. 33 (2005), 491–500.
70. [70] Wang, J., Ma, Z., Hong, Z., Song, J., Tissue distribution in mice of danshensu from sodium danshensu and Salvia miltiorrhizainjection. Zhongguo Zhong Yao Za Zhi 36 (2011), 1516–1518 (Article in Chinese).
71. [71] Li, H., Song, F., Duan, L.R., Sheng, J.J., Xie, Y.H., Yang, Q., Chen, Y., Dong, Q.Q., Zhang, B.L., Wang, S.W., Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: roles of Nrf2/HO-1 and PI3K/Akt pathway. Sci. Rep., 6, 2016, 23693.
72. [72] Cui, G., Shan, L., Hung, M., Lei, S., Choi, I., Zhang, Z., Yu, P., Hoi, P., Wang, Y., Lee, S.M., A novel danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways. Int. J. Cardiol. 168 (2013), 1349–1359.
73. [73] Hu, T., Wei, G., Xi, M., Yan, J., Wu, X., Wang, Y., Zhu, Y., Wang, C., Wen, A., Synergistic cardioprotective effects of danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway. Int. J. Mol. Med. 38 (2016), 83–94.
74. [74] Yu, J., Wang, L., Akinyi, M., Li, Y., Duan, Z., Zhu, Y., Fan, G., Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling. Int. J. Clin. Exp. Med. 8 (2015), 14793–14804.
75. [75] Reddy, M.A., Zhang, E., Natarajan, R., Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58 (2015), 443–455.
76. [76] Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002), 2563–2569.
77. [77] Roberts, A.C., Porter, K.E., Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab. Vasc. Dis. Res. 10 (2013), 472–482.
78. [78] Kumar, S., Pamulapati, H., Tikoo, K., Fatty acid induced metabolic memory involves alterations in renal histone H3K36me2 and H3K27me3. Mol. Cell. Endocrinol. 422 (2016), 233–242.
79. [79] Cai, M., Bompada, P., Atac, D., Laakso, M., Groop, L., De Marinis, Y., Epigenetic regulation of glucose-stimulated osteopontin (OPN) expression in diabetic kidney. Biochem. Biophys. Res. Commun. 469 (2016), 108–113.
80. [80] Miao, F., Chen, Z., Genuth, S., Paterson, A., Zhang, L., Wu, X., Li, S.M., Cleary, P., Riggs, A., Harlan, D.M., Lorenzi, G., Kolterman, O., Sun, W., Lachin, J.M., Natarajan, R., DCCT/EDIC Research Group, Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 63 (2014), 1748–1762.
81. [81] Wang, X.H., Qian, R.Z., Zhang, W., Chen, S.F., Jin, H.M., Hu, R.M., MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 36 (2009), 181–188.
82. [82] Caporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G.B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A.H., Agami, R., le Sage, C., Condorelli, G., Madeddu, P., Martelli, F., Emanueli, C., Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123 (2011), 282–291.
83. [83] Puthanveetil, P., Chen, S., Feng, B., Gautam, A., Chakrabarti, S., Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J. Cell. Mol. Med. 19 (2015), 1418–1425.
84. [84] Thethi, T.K., Bajwa, M.A., Ghanim, H., Jo, C., Weir, M., Goldfine, A.B., Umpierrez, G., Desouza, C., Dandona, P., Fang-Hollingsworth, Y., Raghavan, V., Fonseca, V.A., Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. J. Diabetes Complicat. 29 (2015), 433–437.
85. [85] Ma, R., Taruttis, A., Ntziachristos, V., Razansky, D., Multispectral optoacoustic tomography (MSOT) scanner for whole-body small animal imaging. Opt. Express 17 (2009), 21414–21426.
86. [86] iTheraMedical, MSOT Principle. accessed 16.06.08) http://www.ithera-medical.com/technology/msot-principle.html, 2015.
87. [87] Razansky, D., Harlaar, N.J., Hillebrands, J.L., Taruttis, A., Herzog, E., Zeebregts, C.J., van Dam, G.M., Ntziachristos, V., Multispectral optoacoustic tomography of matrix metalloproteinase activity in vulnerable human carotid plaques. Mol. Imaging Biol. 14 (2012), 277–285.
88. [88] Zhu, L., Xie, J., Swierczewska, M., Zhang, F., Quan, Q., Ma, Y., Fang, X., Kim, K., Lee, S., Chen, X., Real-time video imaging of protease expression in vivo. Theranostics 1 (2011), 18–27.